ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,308.15
1.17%
US Tech 100
18,138.80
1.69%
다우존스 지수
39,908.00
0.88%
Bitcoin
66,034.57
-0.35%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Acrivon Therapeutics Inc (ACRV)

  7. Acrivon Therapeutics Inc (ACRV) 뉴스

ACRV

Acrivon Therapeutics (ACRV)

Acrivon Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:ACRV
일자시간출처헤드라인심볼기업
2024/05/1421:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
2024/05/1421:00GlobeNewswire Inc.Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:ACRVAcrivon Therapeutics Inc
2024/05/1420:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACRVAcrivon Therapeutics Inc
2024/04/2505:01GlobeNewswire Inc.Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D EventNASDAQ:ACRVAcrivon Therapeutics Inc
2024/04/1709:01GlobeNewswire Inc.Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316NASDAQ:ACRVAcrivon Therapeutics Inc
2024/04/1021:00GlobeNewswire Inc.Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable ResistancNASDAQ:ACRVAcrivon Therapeutics Inc
2024/04/0920:00GlobeNewswire Inc.Acrivon Therapeutics Announces $130 Million Private Placement FinancingNASDAQ:ACRVAcrivon Therapeutics Inc
2024/03/2821:00GlobeNewswire Inc.Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsNASDAQ:ACRVAcrivon Therapeutics Inc
2024/03/0706:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
2024/03/0706:29Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
2024/03/0606:30GlobeNewswire Inc.Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316NASDAQ:ACRVAcrivon Therapeutics Inc
2024/03/0422:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
2024/03/0422:00GlobeNewswire Inc.Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of DirectorsNASDAQ:ACRVAcrivon Therapeutics Inc
2024/02/2722:00GlobeNewswire Inc.Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care ConferenceNASDAQ:ACRVAcrivon Therapeutics Inc
2024/02/1707:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
2024/02/1707:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
2024/02/1707:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
2024/02/1707:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
2024/02/1707:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
2024/02/1707:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
2024/02/1405:40Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ACRVAcrivon Therapeutics Inc
2024/02/0822:27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
2024/02/0822:00GlobeNewswire Inc.Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of DirectorsNASDAQ:ACRVAcrivon Therapeutics Inc
2024/02/0622:00GlobeNewswire Inc.Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ACRVAcrivon Therapeutics Inc
2024/01/2006:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
2024/01/1306:00GlobeNewswire Inc.Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACRVAcrivon Therapeutics Inc
2024/01/0821:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
2024/01/0422:00GlobeNewswire Inc.Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ACRVAcrivon Therapeutics Inc
2023/12/1814:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ACRVAcrivon Therapeutics Inc
2023/12/0906:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
 검색 관련기사 보기:NASDAQ:ACRV

최근 히스토리

COIN
BTCUSD
Bitcoin
AMEX
SPY
SPDR S&P 500
CCOM
US500
US 500
NASDAQ
GOOGL
Alphabet
NASDAQ
MSFT
Microsoft
NYSE
VZ
Verizon Communications
NYSE
DIS
Walt Disney
AMEX
XLV
Health Care Select Sector
USOTC
RHHBY
Roche (QX)
NYSE
MRK
Merck
NYSE
XOM
Exxon Mobil
NYSE
MCD
McDonalds
USOTC
DTEGY
Deutsche Telekom (QX)
USOTC
BASFY
BASF (QX)
NYSE
AXP
American Express
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유